We read with interest the letter from Dai and coworkers related to the potential reflux-related complications of esophageal stents. However, the complications the authors described were related to long-term esophageal stents used to treat benign or malign strictures of the esophagus, which is not the case. In fact, the stents used to control acute esophageal variceal bleeding are specifically designed for this severe complication and are removable stents, which can remain in place from 6 to 14 days. Moreover, they were also used to treat esophageal tears caused by a previous balloon tamponade. (1,2) As stated by the authors, all patients developing acute variceal bleeding are placed in a slightly upright position to avoid aspiration of the gastric content, which, unfortunately, occurred in one patient in the stent group. However, this adverse event could be attributed to the presence of hematemesis, upper endoscopy, placement of the stent, etc. As mentioned in the article, aspiration was more frequent in the group of patients treated by esophageal balloon tamponade than in those receiving esophageal metal stents. 
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HCVg3 infections are more difficult to treat with direct-acting antivirals. The reason for this is unknown, but could be explained by a distinct pattern of RAVs and an increase in the prevalence of "favorable" IFNL4 SNPs in this genotype. Here, we used a large cohort of 496 HCVg3a-infected patients (from the BOSON clinical study (2) ) and report no significant association (P > 0.05) between the treatmentbeneficial C/C genotype of INFL4 and RAV site Y93H in the NS5A gene.
Using next-generation sequencing, (3) baseline viral sequences from 556 BOSON patients chronically infected with either HCVg2 or HCVg3 were obtained. The INFL4 SNP rs12979860 was also genotyped. The cohort (total of 556) was composed of 49 (8.8%) HCVg2-and 507 (91.2%) HCVg3-infected patients, of which 496 (89.2%) were subtype 3a.
Substitutions in the quasi-species at Y93 (Y93H) were only observed in HCVg3a-infected patients; therefore, the analysis was done on this subset of the data. The Y93H RAV was present in 11.1% (55 of 496) of the genotype 3a-infected patients; in 4.7% (23 of 496), Y93H was as the majority variant. There was no significant association between the presence of H (either as the consensus level or at any level of detection) and the beneficial C/C genotype of INFL4 (P > 0.05; 
